Zhang Linqi, Liu Zhidong, Jiang Shuqin, He Qiao, Zhang Rusen
From the Department of Nuclear Medicine, Affiliated Cancer Hospital & Institute of Guangzhou Medical University.
Department of Nuclear Medicine, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Clin Nucl Med. 2022 Oct 1;47(10):e651-e653. doi: 10.1097/RLU.0000000000004275. Epub 2022 May 19.
A 56-year-old woman presented with primary undifferentiated pleomorphic sarcoma of colon mesentery underwent complete surgical resection approximately 7 months ago. Abdominal contrast-enhanced CT showed a new mass in the descending colon, suggesting a high probability of tumor recurrence. Under a clinical trial, the patient underwent 68 Ga-FAPI and 18 F-FDG PET/CT to detect whether there are additional recurrent lesions. Compared with 18 F-FDG PET/CT, the recurrent undifferentiated pleomorphic sarcoma of colon mesentery, peritoneum, pelvic lymph node, and lung metastases showed higher uptake in 68 Ga-FAPI PET/CT. This case showed that 68 Ga-FAPI might be a promising radiopharmaceutical in the evaluation of undifferentiated pleomorphic sarcoma.
一名56岁女性，约7个月前因原发性结肠系膜未分化多形性肉瘤接受了完整的手术切除。腹部增强CT显示降结肠有一个新肿块，提示肿瘤复发的可能性很高。在一项临床试验中，该患者接受了68Ga-FAPI和18F-FDG PET/CT检查，以检测是否存在其他复发病灶。与18F-FDG PET/CT相比，结肠系膜、腹膜、盆腔淋巴结和肺转移的复发性未分化多形性肉瘤在68Ga-FAPI PET/CT上摄取更高。该病例表明，68Ga-FAPI可能是一种有前景的放射性药物，用于评估未分化多形性肉瘤。
